Gerri Henwood President and Chief Executive Officer

Gerri Henwood

Gerri Henwood has served as our president and chief executive officer and a director of the company since our inception in 2008. Henwood also serves as chief executive officer and a director of Baudax Bio.

From 2006 to 2013, Henwood served as the president of Malvern Consulting Group (MCG), a pharmaceutical incubator and consulting firm. Henwood continues to spend a very small portion of her time engaged in the provision of consulting services for MCG to other companies, including those engaged in the development and commercialization of other pharmaceutical products.

From 1999 to 2006, Henwood was the president and chief executive officer of Auxilium Pharmaceuticals, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Henwood was the founder and chief executive officer of IBAH, a contract research organization. IBAH reached a net revenue level of $150 million as a NASDAQ-traded company before being acquired by Omnicare in 1998.

Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline, in the pharmaceutical management program. She rose through the ranks to be a brand manager, then the head of regulatory and medical affairs for the U.S. business and then to the position of group director, marketing in the international pharmaceutical division.

Since May 2015, Henwood has served on the board of directors of Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company, where she also serves on the compensation committee. She is also on the board of two private companies and previously served on the board of directors of Alkermes, Inc., and its successor company, Alkermes plc, a global biopharmaceutical company, from 2003 to March 2015. Henwood holds a B.S. in biology from Neumann University.

As our founder and having served as a director since our inception, Henwood provides extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise born of developing, financing, and providing strong executive leadership to numerous biopharmaceutical companies. Combined with Henwood’s strong background in clinical and product development and substantial knowledge of the pharmaceutical industry, these qualities contributed to our Board’s conclusion that she should serve as a director of our company.